Journal
CLINICAL IMMUNOLOGY
Volume 123, Issue 2, Pages 121-128Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2006.09.016
Keywords
HIV; interferon; dendritic cells; apoptosis; TRAIL; T cells; lymphoid tissue; DR5; nonprogressor
Categories
Funding
- NCI NIH HHS [Z01 BC009267-23] Funding Source: Medline
Ask authors/readers for more resources
The hallmark of acquired immunodeficiency syndrome (AIDS) is the progressive loss of CD4(+) T cells that results from infection with human immunodeficiency virus type-1 (HIV-1). Despite 25 years of AIDS research, questions remain concerning the mechanisms responsible for HIV-induced CD4(+) T cell depletion. Here we briefly review the in vitro and in vivo literature concerning the protective rote of interferon -alpha (IFN-alpha) in HIV/AIDS. We then develop a laboratory- and clinically supported model of CD4(+) T cell apoptosis in which either infectious or noninfectious HIV-1 induces the production of type I interferon by plasmacytoid dendritic cells (pDC). The interferon produced binds to its receptor on primary CD4(+) T cells resulting in membrane expression of the TNF-retated apoptosis-inducing ligand (TRAIL) death molecule. The binding of infectious or noninfectious HIV-1 to CD4 on these T cells results in expression of the TRAIL death receptor 5 (DR5), leading to the selective death of HIV-exposed CD4(+) T cells. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available